GlassScriptPhysician profile
Sylvia Cristina Rivera
NPI 1932424702
$2,106.40
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $338 · 2021: $160 · 2023: $270 · 2024: $442 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Long Term Medical Supply Or Device Loan: $110 · Education: $60.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.55 |
| Long Term Medical Supply Or Device Loan | $109.98 |
| Education | $60.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $494.73 | 2019-2025 | Evenity |
| Medtronic, INC. | $274.29 | 2021-2023 | Minimed 780g |
| Abbott Laboratories | $234.18 | 2019-2024 | Freestyle Copilot, Precision Xtra, Freestyle Libre 3 |
| Novo Nordisk INC | $150.06 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $124.90 | 2019-2020 | |
| Medtronic Minimed, INC. | $99.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $82.31 | 2019-2020 | |
| Corcept Therapeutics | $81.22 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $77.13 | 2021 | |
| Abbvie INC. | $71.59 | 2019 | |
| Companion Medical, INC. | $59.70 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $46.20 | 2019-2020 | |
| Lilly USA, LLC | $33.95 | 2019 | |
| Ascensia Diabetes Care US INC. | $32.62 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.88 | 2019-2020 | |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.85 | 2023 | |
| Mannkind Corporation | $19.49 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.11 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2019 | |
| Insulet Corporation | $18.63 | 2024 | Omnipod |
| Ibsa Pharma INC. | $16.40 | 2019 | |
| Merck Sharp & Dohme LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.